2ZY1 image
Deposition Date 2009-01-10
Release Date 2009-09-01
Last Version Date 2023-11-01
Entry Detail
PDB ID:
2ZY1
Keywords:
Title:
Crystal structure of the C(30) carotenoid dehydrosqualene synthase from Staphylococcus aureus complexed with bisphosphonate BPH-830
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.78 Å
R-Value Free:
0.21
R-Value Work:
0.18
Space Group:
P 32 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Dehydrosqualene synthase
Gene (Uniprot):crtM
Chain IDs:A
Chain Length:293
Number of Molecules:1
Biological Source:Staphylococcus aureus
Ligand Molecules
Primary Citation
Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results.
J.Med.Chem. 52 3869 3880 (2009)
PMID: 19456099 DOI: 10.1021/jm9001764

Abstact

The gold color of Staphylococcus aureus is derived from the carotenoid staphyloxanthin, a virulence factor for the organism. Here, we report the synthesis and activity of a broad variety of staphyloxanthin biosynthesis inhibitors that inhibit the first committed step in its biosynthesis, condensation of two farnesyl diphosphate (FPP) molecules to dehydrosqualene, catalyzed by the enzyme dehydrosqualene synthase (CrtM). The most active compounds are phosphonoacetamides that have low nanomolar K(i) values for CrtM inhibition and are active in whole bacterial cells and in mice, where they inhibit S. aureus disease progression. We also report the X-ray crystallographic structure of the most active compound, N-3-(3-phenoxyphenyl)propylphosphonoacetamide (IC(50) = 8 nM, in cells), bound to CrtM. The structure exhibits a complex network of hydrogen bonds between the polar headgroup and the protein, while the 3-phenoxyphenyl side chain is located in a hydrophobic pocket previously reported to bind farnesyl thiodiphosphate (FsPP), as well as biphenyl phosphonosulfonate inhibitors. Given the good enzymatic, whole cell, and in vivo pharmacologic activities, these results should help guide the further development of novel antivirulence factor-based therapies for S. aureus infections.

Legend

Protein

Chemical

Disease

Primary Citation of related structures